High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Abstract

We plan to study the higher dose-intensity 500-mg/m2 level on good-risk and carefully monitored patients. This could enlarge the spectrum of tumors sensitive to irinotecan and improve the already good results observed in colorectal cancers.